COSM Cosmos Health Inc.
Price Chart
Executive Summary
Cosmos Health subsidiary Cana Laboratories inaugurated a new capsule production line and secured a five-year contract manufacturing agreement with Provident Pharmaceuticals to produce 385,000 units of CERTORUN® (sertraline HCl) at 77,000 units annually. The deal builds on an existing relationship and adds recurring, high-margin revenue, but financial terms were not disclosed and the absolute production volume is modest relative to the company's scale.
Actionable Insight
The contract adds predictable recurring revenue but is too small in absolute unit volume (77k/year) to materially move the needle for a $14M market cap company. Monitor future 10-Q for actual revenue contribution from this agreement and any additional contract wins that could scale the manufacturing segment.
Key Facts
- Cana Laboratories secured a five-year contract manufacturing agreement with Provident Pharmaceuticals for 385,000 units of CERTORUN® (sertraline HCl) at 77,000 units per year.
- Production will use Cana's newly installed ACG capsule-filling line.
- This agreement follows prior contracts for DE3-SOLE®, MIOREL®, CALCIFOLIN®, and DEXA-DOSE®.
- No financial terms (revenue, margin, or upfront payment) were disclosed.
Financial Impact
Undisclosed — no revenue, margin, or dollar value provided for the contract.
Risk Factors
- Financial terms undisclosed — actual revenue impact may be negligible.
- Dependence on single counterparty (Provident) for this contract.
- Execution risk on new production line ramp-up.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309295 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 17, 2026
1d ago
|
Press Release
| $0.2417 $0.2129 | ▼ −11.92% | ▼ −12.70% | $0.2420 (+0.12%) |
|
Jun 12, 2026
6d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2420 (+15.24%) |
|
Jun 12, 2026
6d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2420 (+15.24%) |
|
Jun 10, 2026
8d ago
|
Press Release
| $0.2281 $0.2060 | ▼ −9.69% | ▼ −11.39% | $0.2420 (+6.09%) |
|
Jun 9, 2026
9d ago
|
Press Release
| $0.2233 $0.2281 | ▲ +2.15% | ▲ +3.73% | $0.2420 (+8.37%) |
|
Jun 8, 2026
10d ago
|
Press Release
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2420 (+5.22%) |
|
Jun 6, 2026
13d ago
|
S-3/A
| $0.2300 $0.2233 | ▲ +2.91% | ▲ +2.62% | $0.2420 (−5.22%) |
|
Jun 5, 2026
13d ago
|
DEFA14A
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2420 (+5.22%) |
|
Jun 1, 2026
17d ago
|
Press Release
| $0.2530 $0.2610 | ▲ +3.16% | ▲ +3.02% | $0.2420 (−4.35%) |
|
May 26, 2026
23d ago
|
Press Release
| $0.2630 $0.2650 | ▲ +0.76% | ▲ +0.75% | $0.2420 (−7.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access